Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fagundo, Ana B ^a,b   de la Torre, Rafael ^b,c   Jiménez Murcia, Susana ^a,b,d   Agüera, Zaida ^b   Pastor, Antoni ^c,e   Casanueva, Felipe F ^b,f   Granero, Roser ^b,e   Baños, Rosa ^b,g   Botella, Cristina ^b,h   de Pino Gutierrez, Amparol ^a,d   Fernández Real, Jose M ^b,i   Fernández García, Jose C ^b,j   Frühbeck, Gema ^b,k   Gómez Ambrosi, Javier ^b,k   Menchón, José M ^a,d,l   Moragrega, Inés ^b,h   Rodríguez, Roser ^b,i   Tárrega, Salomé ^e   Tinahones, Francisco J ^b,j   Fernández Aranda, Fernando ^a,b,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g UNIVERSITY OF VALENCIA   (Spain)

^h UNIVERSITAT JAUME I   (Spain)

ⁱ GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^k UNIVERSITY CLINIC OF NAVARRA   (Spain)

^l CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE; N-ARACHIDONOYLETHANOLAMINE;

ADULT; ARTICLE; BLOOD LEVEL; COGNITIVE FLEXIBILITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DECISION MAKING; EXECUTIVE FUNCTION; FEMALE; HUMAN; HUMAN EXPERIMENT; IOWA GAMBLING TASK; MENTAL TASK; NEUROMODULATION; NORMAL HUMAN; RESPONSE INHIBITION; STROOP TEST; TASK PERFORMANCE; WISCONSIN CARD SORTING TEST; BLOOD; COGNITION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; YOUNG ADULT;

ANIMALIA;

ADULT; ARACHIDONIC ACIDS; COGNITION; DECISION MAKING; ENDOCANNABINOIDS; EXECUTIVE FUNCTION; FEMALE; GLYCERIDES; HUMANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; YOUNG ADULT;

EID: 84879245952     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066387     Document Type: Article

References (81)

1. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, et al. (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25: 2874-2884.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
3. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
4. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, et al. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
5. Di Marzo V, (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci 14: 9-15.
6. Leung D, Saghatelian A, Simon GM, Cravatt BF, (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45: 4720-4726.
7. Petrosino S, Ligresti A, Di Marzo V, (2009) Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol 2009 13: 309-320.
8. Di Marzo V, Maccarrone M, (2008) FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 29: 229-233.
9. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463-468.
10. Nomura DK, Hudak CS, Ward AM, Burston JJ, Issa RS, et al. (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett 18: 5875-5878.
11. Di Marzo V, Matias I, (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
12. De Vries TJ, Schoffelmeer AN, (2005) Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26: 420-426.
13. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
14. Takahashi RN, Pamplona FA, Fernandes MS, (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380: 270-275.
15. Varvel SA, Anum EA, Lichtman AH, (2005) Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice. Psychopharmacology (Berl) 179: 863-872.
16. Egertova M, Elphick MR, (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422: 159-171.
17. Miller EK, Cohen JD, (2001) An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24: 167-202.
18. Hajos N, Freund TF, (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121: 73-82.
19. Herkenham M, (1992) Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 654: 19-32.
20. Mato S, Pazos A, (2004) Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46: 716-726.
21. Di Marzo V, Bisogno T, De Petrocellis L, (2000) Endocannabinoids: new targets for drug development. Curr Pharm Des 6: 1361-1380.
22. Egertova M, Cravatt BF, Elphick MR, (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119: 481-496.
23. Di Marzo V, De Petrocellis L, Bisogno T, Melck D, (1999) Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids 34Suppl: S319-325.
24. Beltramo M, Piomelli D, (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11: 1231-1235.
25. Egerton A, Allison C, Brett RR, Pratt JA, (2006) Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 30: 680-695.
26. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, et al. (2005) Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30: 508-515.
27. Hill MN, Froese LM, Morrish AC, Sun JC, Floresco SB, (2006) Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists. Psychopharmacology (Berl) 187: 245-259.
28. Egerton A, Brett RR, Pratt JA, (2005) Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology 30: 1895-1905.
29. Klugmann M, Goepfrich A, Friemel CM, Schneider M, (2011) AAV-Mediated Overexpression of the CB1 Receptor in the mPFC of Adult Rats Alters Cognitive Flexibility, Social Behavior, and Emotional Reactivity. Front Behav Neurosci 5: 37.
30. Sokolic L, Long LE, Hunt GE, Arnold JC, McGregor IS, (2011) Disruptive effects of the prototypical cannabinoid Delta(9)-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. Behav Pharmacol 22: 191-202.
31. McDonald J, Schleifer L, Richards JB, de Wit H, (2003) Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28: 1356-1365.
32. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ, (2005) Acute marijuana effects on human risk taking. Neuropsychopharmacology 30: 800-809.
33. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, et al. (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31: 2296-2303.
34. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, et al. (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 64: 966-973.
35. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, et al. (1996) Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res 67: 29-38.
36. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, et al. (1999) Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 100: 67-75.
37. Mathew RJ, Wilson WH, Turkington TG, Hawk TC, Coleman RE, et al. (2002) Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res 116: 173-185.
38. Eldreth DA, Matochik JA, Cadet JL, Bolla KI, (2004) Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 23: 914-920.
39. Gruber SA, Yurgelun-Todd DA, (2005) Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res 23: 107-118.
40. Bolla KI, Eldreth DA, Matochik JA, Cadet JL, (2005) Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 26: 480-492.
41. Fagundo AB, de la Torre R, Jimenez-Murcia S, Aguera Z, Granero R, et al. (2012) Executive functions profile in extreme eating/weight conditions: from anorexia nervosa to obesity. PLoS One 7: e43382.
42. Heaton RK (1981) Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources.
43. Golden CJ (1978) Stroop Color and Word Test: Manual for Clinical and Experimental Uses. Chicago, IL: Stoeling.
44. Bechara A, Damasio H, Tranel D, Damasio AR, (1997) Deciding advantageously before knowing the advantageous strategy. Science 275: 1293-1295.
45. Gligorovic M, Buha N (2013) Conceptual abilities of children with mild intellectual disability: Analysis of Wisconsin Card Sorting Test performance. J Intellect Dev Disabil.
46. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, et al. (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
47. Pattij T, Janssen MC, Schepers I, Gonzalez-Cuevas G, de Vries TJ, et al. (2007) Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats. Psychopharmacology (Berl) 193: 85-96.
48. Varvel SA, Lichtman AH, (2002) Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301: 915-924.
49. Lacroix L, White I, Feldon J, (2002) Effect of excitotoxic lesions of rat medial prefrontal cortex on spatial memory. Behav Brain Res 133: 69-81.
50. Lafenetre P, Chaouloff F, Marsicano G, (2009) Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system. Neuropharmacology 57: 715-721.
51. Lundqvist T, (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81: 319-330.
52. Crean RD, Crane NA, Mason BJ, (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5: 1-8.
53. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D, (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58: 909-915.
54. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL, (2002) Dose-related neurocognitive effects of marijuana use. Neurology 59: 1337-1343.
55. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, et al. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. Jama 287: 1123-1131.
56. Whitlow CT, Liguori A, Livengood LB, Hart SL, Mussat-Whitlow BJ, et al. (2004) Long-term heavy marijuana users make costly decisions on a gambling task. Drug Alcohol Depend 76: 107-111.
57. Ashton CH, Moore PB, (2011) Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 124: 250-261.
58. Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, et al. (2009) Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8: 2.
59. Pazos MR, Sagredo O, Fernandez-Ruiz J, (2008) The endocannabinoid system in Huntington's disease. Curr Pharm Des 14: 2317-2325.
60. Ohno-Shosaku T, Maejima T, Kano M, (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29: 729-738.
61. Wilson RI, Nicoll RA, (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410: 588-592.
62. Schlicker E, Kathmann M, (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572.
63. Gerdeman GL, Ronesi J, Lovinger DM, (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5: 446-451.
64. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ, (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 99: 8384-8388.
65. Pistis M, Muntoni AL, Pillolla G, Gessa GL, (2002) Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 15: 1795-1802.
66. Verrico CD, Jentsch JD, Roth RH, (2003) Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49: 61-66.
67. Diana M, Melis M, Gessa GL, (1998) Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10: 2825-2830.
68. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30: 1963-1985.
69. Stefani MR, Groth K, Moghaddam B, (2003) Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav Neurosci 117: 728-737.
70. Stefani MR, Moghaddam B, (2003) Distinct contributions of glutamate receptor subtypes to cognitive set-shifting abilities in the rat. Ann N Y Acad Sci 1003: 464-467.
71. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, et al. (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11: 152-159.
72. Starowicz K, Nigam S, Di Marzo V, (2007) Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114: 13-33.
73. Rubino T, Parolaro D, (2011) Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci 5: 64.
74. Rubino T, Vigano D, Realini N, Guidali C, Braida D, et al. (2008) Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33: 2760-2771.
75. Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ, (2010) Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol 161: 103-112.
76. Luchicchi A, Pistis M, (2012) Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 46: 374-392.
77. Danner UN, Ouwehand C, van Haastert NL, Hornsveld H, de Ridder DT, (2012) Decision-making impairments in women with binge eating disorder in comparison with obese and normal weight women. Eur Eat Disord Rev 20: e56-62.
78. Tchanturia K, Liao PC, Forcano L, Fernandez-Aranda F, Uher R, et al. (2012) Poor decision making in male patients with anorexia nervosa. Eur Eat Disord Rev 2012 20: 169-173.
79. Gaetani S, Kaye WH, Cuomo V, Piomelli D, (2008) Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 13: e42-48.
80. Monteleone P, Bifulco M, Di Filippo C, Gazzerro P, Canestrelli B, et al. (2009) Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. Genes Brain Behav 8: 728-732.
81. Stoving RK, Andries A, Brixen K, Flyvbjerg A, Horder K, et al. (2009) Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. J Psychiatr Res 43: 671-679.